Howard Herrmann, MD,  MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.

Food insecurity—lacking consistent access to the food needed to live an “active, healthy lifestyle”—impacts up to one in eight Americans each year. 

Clinicians are asking the world's medical societies to come together and agree on one acronym for TAVR/TAVI to avoid unnecessary confusion going forward.

TAVR adoption in Africa has been relatively slow, but cardiologists throughout the continent have made considerable progress. New data does show that there is some work to be done before outcomes will rival what is seen in many other parts of the world.

TAVR is associated with a significantly lower risk of bioprosthetic valve dysfunction than SAVR, according to new data presented at CRT 2025 and simultaneously published in JACC. 

Researchers presented new two-year data from the SMART trial at CRT 2025 in Washington, D.C. Overall, self-expanding TAVR valves continue to show superior valve performance compared to balloon-expandable valves, and clinical outcomes remain comparable.

Two separate groups have published new research comparing early AVR with clinical surveillance for the treatment of asymptomatic severe aortic stenosis. Overall, the two groups found, early treatment was associated with multiple benefits—and no added risk of harm.

SCAI President James Hermiller, Jr., MD, explains the need for more innovative radiation protection systems in the cath lab.